Equities

Innovita Biological Technology Co Ltd

688253:SHH

Innovita Biological Technology Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)40.59
  • Today's Change-0.79 / -1.91%
  • Shares traded2.26m
  • 1 Year change+61.20%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Innovita Biological Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of point-of-care testing (POCT) rapid diagnostic products. The Company's main products include novel coronavirus (2019-nCoV) neutralizing antibody detection kits using colloidal gold, quantum dot fluorescence immunochromatography and chemiluminescence techniques, and respiratory pathogen detection products, such as whole blood respiratory quintuple detection card, influenza virus triple detection card, virus serum quintuple detection card, respiratory pathogen nine indirect immunofluorescence kit, and others.

  • Revenue in CNY (TTM)625.12m
  • Net income in CNY266.22m
  • Incorporated2006
  • Employees404.00
  • Location
    Innovita Biological Technology Co LtdBEIJING 100071ChinaCHN
  • Phone+86 1 083682249
  • Fax+86 1 083682966
  • Websitehttps://www.innovita.com.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Jibeier Pharmaceutical Co Ltd889.82m233.59m5.08bn1.45k21.602.59--5.711.241.244.7410.370.4263.135.33615,794.8011.179.7712.0610.6687.8788.4426.2223.296.76--0.00530.6831.4912.1641.6517.79112.78--
Beijing Kawin Technol Sha-hld Co Ltd1.43bn117.53m5.16bn584.0042.762.85--3.600.70610.70618.6110.600.62641.664.422,451,945.006.115.317.696.7682.3586.029.768.103.25--0.080943.8221.7314.8739.7121.0425.01--
Shanghai Haixin Group Co Ltd1.11bn171.70m5.23bn760.0040.781.77--4.710.14220.14220.91853.270.22467.199.321,458,849.004.052.684.573.0646.3744.5518.0211.172.83--0.008936.10-17.881.481.204.19-10.2713.18
HitGen Inc409.13m64.05m5.24bn452.0082.093.80--12.810.15930.15931.023.440.2416.704.84905,165.503.774.634.025.1051.4658.8915.6620.6614.48360.770.14219.1412.6419.6961.16-1.96-6.12--
Hunan Fangsheng Pharmaceutical Co Ltd1.63bn193.23m5.29bn1.69k27.173.44--3.240.44280.44283.723.490.52271.486.56966,866.905.935.399.729.3767.7566.9111.348.950.552716.410.344746.47-9.129.15-34.6420.6823.914.75
Shanghai Hile Bio-Technology Co Ltd239.79m44.92m5.31bn295.00120.634.25--22.140.06690.06690.36641.900.1541.062.40812,857.502.061.732.562.4745.1950.4413.3710.371.16--0.056223.89-19.76-1.11-48.3024.17-41.3223.47
InventisBio Co Ltd194.13m-249.28m5.42bn221.00--2.80--27.92-0.4289-0.42890.33483.350.0898--1.96878,429.50-11.53---12.26--97.85---128.41------0.0054------41.26------
Innovita Biological Technology Co Ltd625.12m266.22m5.52bn404.0020.752.78--8.831.961.964.5914.620.30931.676.231,547,324.0013.17--14.20--80.99--42.59--10.66--0.0015--7.03--15.44------
Zhejiang Shouxiangu Pharmaceuticl Co Ltd799.09m269.00m5.65bn1.14k20.372.44--7.071.371.374.0811.490.25730.90166.83699,118.908.6610.0410.4811.6381.3183.6633.6628.293.33--0.254747.86-5.398.93-8.3918.7812.2317.13
Beijing Sun-Novo Pharma Research Co Ltd951.95m209.57m5.82bn1.37k27.755.73--6.111.871.878.509.060.546526.191.77694,854.3011.7012.9919.1321.7059.1053.9321.4021.341.7745.000.372110.7437.7647.2218.0854.9034.77--
Sichuan Huiyu Pharmaceutical Co Ltd931.96m147.83m5.98bn1.36k40.431.57--6.410.3490.3492.209.010.20320.912114.88683,254.603.1810.413.8212.7684.4689.8915.6521.422.92--0.129920.54-37.9276.37-43.86--66.72--
Data as of May 17 2024. Currency figures normalised to Innovita Biological Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

8.71%Per cent of shares held by top holders
HolderShares% Held
China Asset Management Co., Ltd.as of 31 Dec 20231.48m4.95%
Rongtong Fund Management Co., Ltd.as of 31 Dec 2023604.14k2.02%
Hui'an Fund Management Co. Ltd.as of 30 Jun 2023236.00k0.79%
China Merchants Fund Management Co., Ltd.as of 31 Dec 2023215.69k0.72%
Essence Fund Co., Ltd.as of 31 Dec 202323.61k0.08%
Caitong Fund Management Co., Ltd.as of 30 Jun 202311.76k0.04%
Penghua Fund Management Co., Ltd.as of 31 Dec 20239.13k0.03%
Ping An Fund Management Co., Ltd.as of 31 Dec 20238.76k0.03%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20238.73k0.03%
Bosera Asset Management Co., Ltd.as of 31 Dec 20237.95k0.03%
More ▼
Data from 30 Jun 2023 - 16 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.